Biopharma · Process Development

Bioprocess Scale Down Model (SDM) vs Commercial Scale:
Introduction, Limitations and Goals

In biopharmaceutical manufacturing, demonstrating that a process is well understood and adequately controlled to maintain high product quality is core objective of commercial-scale operations — but getting there comes at a steep cost. Scale Down Models bridge that gap, enabling data-driven prediction of commercial performance at a fraction of cost.

Topic: Scale Down Modeling Level: Advanced Application: CMC, Process Development, Pharma

Commercial Scale: The Core Challenge

Full-scale commercial bioprocessing represents the gold standard for manufacturing quality medicines — but it is among the most resource-intensive environments in modern industry. Operating at this scale requires vast infrastructure, large volumes of raw materials, and significant time investment for every experimental cycle.

Commercial Scale : Realities

Single batch volume upwards of 20,000 L (20 kL)

Cost of millions of dollars per batch

Expensive and slow to run experiments

Difficult and costly to iterate on process changes

Requires validated large volumes of materials

Scale Down Model : Advantages

Operates at volumes as low as 250 mL

Fraction of the cost per experiment

Fast, iterative experimental cycles

Enables high-throughput process development

Predictive of commercial performance

Warning: A single commercial-scale batch can have a volume upwards of 20 kL and cost millions of dollars — making experimental agility at full scale practically impossible.

SDM Goal: Predictive Small-Scale Representation

The Scale Down Model is not merely a smaller version of manufacturing equipment — it is a scientifically grounded framework designed to replicate and predict behaviour of full-scale process with precision.

Develop Representations

Build scaled-down unit operations that are predictive of key large-scale process features.

Confirm Scaling Principles

Validate engineering scaling predictions through dedicated qualification studies.

Accelerate Development

Perform most experimental work on the small-scale system to infer large-scale process properties.

What Is a Scale Down Representation?

A scale down representation combines smaller physical equipment with a rigorous engineering model that links laboratory and commercial scales. It must satisfy several key criteria to be considered valid:

Operates with smaller equipment and/or volumes — e.g., a 250 mL bioreactor representing a 20,000 L commercial vessel
Supported by an engineering SDM linking large and small scales per established scaling principles
Is predictive of commercial scale performance at target conditions on key features of interest
Is expected to be predictive of commercial scale off-target behaviour based on the SDM, prior experience, expert knowledge, simulation and literature

Important Note: The SDM is MORE than the engineering scaling equations alone. A SDM may be partial — not every aspect of full-scale is modelled. Some unit operations do not need to be scaled down at all (e.g., vial thaw).

Regulatory Framework for Small-Scale Models

Multiple global regulatory bodies have provided guidance on the use and justification of small-scale models. Each emphasises scientific rigor, representativeness, and documented justification.

ICH Q11

Step 4 · May 2012

"Small-scale models can be developed and used to support process development studies. The development of a model should account for scale effects and be representative of proposed commercial process. A scientifically justified model can enable a prediction of quality and can be used to support the extrapolation of operating conditions across multiple scales and equipment."

EMA GUIDELINE

Biotechnology · Nov 2016

"A small-scale model must be designed and executed, and ultimately justified, as an appropriate representation of the manufacturing process. When used, small-scale models should be described and their relevance for the commercial scale should be justified, in terms of objective, design, inputs and outputs."

US FDA GUIDANCE

Process Validation · Jan 2011

"It is important to understand the degree to which models represent the commercial process, including any differences that might exist, as this may have an impact on the relevance of information derived from the models."

Graphtal's SDM Qualification Approach

Graphtal offers a comprehensive suite of advanced analytics solutions specifically designed to support the scale-down model qualification process in bioprocesses — particularly for monoclonal antibody (mAb) development.

SDM Qualification Workflow

Data Mining

Manufacturing scale and small scale data compilation

Define scale down operating process parameters

Perform scale down model qualification runs

Scale down model qualification

Statistical Tools: Comparative analysis, Equivalence Test and MVDA

Demonstrate Scale down equivalency

Qualified scale down model

Statistical Analysis & TOST

Data analysis, statistical support, and equivalence margin setting for both SDM and full-scale processes using Two One-Sided Tests (TOST).

MVDA Integration

Multivariate data analysis to integrate process data, identify patterns, and compare and qualify the scale-down model for improved accuracy.

Sample Size Calculation

Customised EAC and PSD calculations based on available manufacturing batch numbers for statistically valid results.

Ready to qualify your Scale Down Model?

Talk to Graphtal's bioprocess analytics experts and unlock smarter, faster process development.

Get in Touch →

Go Back

Tell Us About Your Project

Our team of experienced professionals at Graphtal is ready to transform your project from idea to
reality, ensuring alignment with your organisation goals through advanced data analytics and
predictive modelling.

Let's simplify your work

Bioprocess Scale Down Model (SDM) vs Commercial Scale: Introduction, Limitations and Goals